Redwood Materials raises $350M to expand US battery recycling and energy storage solutions, contributing to sustainable supply chains and reducing reliance on overseas materials.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Redwood Materials raises $350M to expand US battery recycling and energy storage solutions, contributing to sustainable supply chains and reducing reliance on overseas materials.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.